Persistent mobility disability after neurotoxic chemotherapy
about
Whole-Body Vibration as a Modality for the Rehabilitation of Peripheral Neuropathies: Implications for Cancer Survivors Suffering from Chemotherapy-Induced Peripheral NeuropathyA prospective model of care for breast cancer rehabilitation: functionChemotherapy-induced peripheral neurotoxicity: a critical analysisNeurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptomsProfound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient.Complex impairment of IA muscle proprioceptors following traumatic or neurotoxic injuryMeasuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment ScalePeripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients.Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research.Falls in persons with chemotherapy-induced peripheral neuropathyA prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.Chemotherapy-induced peripheral neuropathy: a literature review.Tumor-targeted nanomedicines for cancer theranostics.Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.Training-related improvements in musculoskeletal health and balance: a 13-week pilot study of female cancer survivors.Impact of oxaliplatin-induced neuropathy: a patient perspective.
P2860
Q26771423-D29A4579-9E0A-48EA-9791-DDA1C1FA2CD0Q26823430-8A638ACF-4B1B-48D8-997C-4E671CE063CAQ27010318-AECBEDAC-4D04-4E65-9D91-F981A1B1AEABQ30361070-2A203482-2DD8-4055-9010-EEF22F4FCA38Q33744706-657C34B2-99D4-44B5-96B3-59DFE7BC404CQ33886036-5475EB08-619E-44F3-B5A0-3DD7C43BD569Q34303792-E526C2DF-23BF-4361-AC1A-A3F917A288B1Q35911716-51420D43-84D9-4983-AB27-B4CF09F6E31EQ36117942-0F293663-921F-43C0-B851-20A440B4D8ADQ36344699-17EEFAD3-CDF3-4018-9E32-F939B062431EQ37365401-75141B3A-AEFF-4D65-865D-E956A3B8CF8DQ37744253-29F5A9E4-151A-48CC-9BF3-4DD6048B88F6Q37744274-78FBD85E-0C3F-44D1-BEE7-1A366672006CQ38001374-810B80BB-D9EE-4AA4-93D6-73836895A7D5Q38694811-6AB0A1A4-37F8-46D5-9D89-C6B3CC7EDB33Q42262385-FDF84856-0557-471C-AEC4-8751B211DD2DQ49203345-B25B255A-D606-4943-B924-89EA93B9F6C0Q50941487-0E563EA0-3CE0-4971-9EE9-DC2F5A56968DQ50956973-9171B7A5-7880-49DE-84BE-5D0E06B1A53D
P2860
Persistent mobility disability after neurotoxic chemotherapy
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Persistent mobility disability after neurotoxic chemotherapy
@ast
Persistent mobility disability after neurotoxic chemotherapy
@en
Persistent mobility disability after neurotoxic chemotherapy
@nl
type
label
Persistent mobility disability after neurotoxic chemotherapy
@ast
Persistent mobility disability after neurotoxic chemotherapy
@en
Persistent mobility disability after neurotoxic chemotherapy
@nl
prefLabel
Persistent mobility disability after neurotoxic chemotherapy
@ast
Persistent mobility disability after neurotoxic chemotherapy
@en
Persistent mobility disability after neurotoxic chemotherapy
@nl
P2860
P921
P356
P1433
P1476
Persistent mobility disability after neurotoxic chemotherapy
@en
P2093
Elizabeth S Hile
Stephanie A Studenski
P2860
P304
P356
10.2522/PTJ.20090405
P577
2010-09-02T00:00:00Z